Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

The K-star opens up on streaming, bold experiments and finding his way back to the stage. Read more at straitstimes.com. Read ...

2025 has come and gone. It was an interesting year and had its fair share of weird Vancouver stories. We’ve gone through some ...

With over 18,000 tokens tracked across centralized and decentralized exchanges, the entire crypto market is worth nearly $3 trillion. This is 31% lower from the all-time high of $4.37 trillion in ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

AI use in Kurdistan is surging, aiding youth employment and trade, but experts warn of privacy risks and future self-teaching ...

Even when no artificial intelligence (AI) is watching, writers are rewriting themselves, flattening their voices, policing ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

Quantum computing stocks are among the hottest plays in the artificial intelligence (AI) industry. Pure-play developers such as Rigetti Computing are among the most popular quantum AI stocks. While ...